These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Why is the efficacy of HAART so durable? Griffiths PD Rev Med Virol; 1999; 9(1):1-2. PubMed ID: 10371666 [No Abstract] [Full Text] [Related]
47. Highlights of the first virtual CROI. Hayward P Lancet HIV; 2020 Apr; 7(4):e227. PubMed ID: 32243825 [No Abstract] [Full Text] [Related]
48. Hydroxyurea in the treatment of human immunodeficiency virus infection. Gelone SP; Kostman JR Am J Health Syst Pharm; 1999 Aug; 56(15):1554-7. PubMed ID: 10478997 [No Abstract] [Full Text] [Related]
49. Cancer drug may join the AIDS arsenal. Voelker R JAMA; 1995 Aug; 274(7):523. PubMed ID: 7629966 [No Abstract] [Full Text] [Related]
50. The Royal Marsden Hospital. Biological therapies. Moore J Nurs Stand; 1990 Aug 8-15; 4(46):53-6. PubMed ID: 2119717 [No Abstract] [Full Text] [Related]
52. Biological treatment approaches, including Tat toxoid vaccine: interview with Robert Gallo, M.D. Interview by John S. James. Gallo R AIDS Treat News; 1999 Sep; (No 327):1-5. PubMed ID: 11366583 [TBL] [Abstract][Full Text] [Related]
53. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. Ensoli B; Fiorelli V; Ensoli F; Cafaro A; Titti F; Buttò S; Monini P; Magnani M; Caputo A; Garaci E AIDS; 2006 Nov; 20(18):2245-61. PubMed ID: 17117011 [No Abstract] [Full Text] [Related]
54. New concepts for future control of HIV derived from studies of pathogenesis. Gallo RC Int J Antimicrob Agents; 2000 Dec; 16(4):421-3. PubMed ID: 11118851 [No Abstract] [Full Text] [Related]
55. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. Fischer M; Joos B; Hirschel B; Bleiber G; Weber R; Günthard HF; J Infect Dis; 2004 Dec; 190(11):1979-88. PubMed ID: 15529263 [TBL] [Abstract][Full Text] [Related]